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 BACKGROUND 
 Leprosy is a chronic granulomatous infectious disease 
caused by  Mycobacterium leprae . The clinical range from 
tuberculoid to lepromatous leprosy is a result of variation 
in the cellular immune response to the Mycobacterium. 1 
Proposed by Ridley and Jopling, disease classiﬁ cation is 
deﬁ ned within two poles with transition between the clin-
ical forms. 2 Clinical, histopathological and immunological 
criteria identify ﬁ ve forms of leprosy: tuberculoid polar 
form, borderline tuberculoid, mid-borderline, borderline 
lepromatous and lepromatous polar leprosy. 3 
 Data taken by the WHO reveal that the prevalence of 
 M leprae infection has been reduced to less than one case 
per 10 000 in 90% of the endemic countries where leprosy 
is considered to be a public health problem. However, new 
case detection rates are still high. Globally 228 474 new 
cases were detected during 2010 in 130 countries and the 
prevalence at the beginning of 2010 was still 192 246 cases. 
Leprosy remains a major problem in some of the emerging 
economies of Asia, Africa and South America. 4 
 Leprosy’s clinical manifestations are primarily conﬁ ned 
to skin and peripheral nerves. However, musculoskel-
etal involvement including inﬂ ammatory arthritis, though 
underreported, is quite common. Joint involvement occurs 
in about 75% of cases of leprosy and at times, is the only 
presenting manifestation. 5 
 Chronic arthritis has been described in Hansen’s dis-
ease but not associated with the presence of bacilli within 
the joint. In the majority of patients, the arthritis fol-
lows a chronic pattern and is not associated with leprosy 
reactions. 
 The role of Mycobacteria in the pathogenesis of rheuma-
toid arthritis (RA) and other types of chronic inﬂ ammation 
has been suggested previously. In particular, mycobacterial 
heat-shock proteins have been considered important tar-
gets of the cellular immune response in patients showing 
symptoms of juvenile arthritis, RA and of antibody pro-
duction in patients with RA. 6 
 Recent studies have demonstrated the presence of anti-
cyclic citrullinated peptide (anti-CCP) antibodies, known 
to have a high speciﬁ city to RA diagnosis, in various infec-
tious diseases such as tuberculosis, leishmaniasis, Hansen’s 
disease and hepatitis. Anti-CCP antibodies were predomi-
nantly observed in patients with tuberculosis, however 
with a great variability and frequently not related with 
articular manifestations. 7 
 CASE PRESENTATION 
 A 47-year-old female patient presented with articular com-
plaints for about 10 years, characterised by symmetric 
polyarthralgia and polyarthritis of the metacarpophalan-
geal (MCF) joints, wrists, knees and tibio-tarsal joints. 
She also had morning stiffness lasting approximately 2 h. 
Concurrent with the onset of joint complaints, she had 
large maculo-papular skin lesions (approximately with 5 
cm in diameter) hypopigmented, with a roughly symmet-
ric distribution, scattered throughout the back, arms and 
face, with central hypoaesthesia. She had no painful or 
thickened nerve routes. 
 At the time, a borderline Hansen’s disease was diag-
nosed by isolation of  M leprae on skin lesions. In this con-
text, she started treatment with dapsone, rifampicin and 
clofazimine with gradual improvement of skin lesions, 
but persistence of articular complaints. According to the 
patient, treatment was completed without complications. 
 She was a heavy smoker since adolescence, of approxi-
mately 30 cigarettes a day. She had no other co-existing 
medical conditions and no chronic medication. No family 
history of autoimmune diseases has been recorded. 
 Over the 10 years of joint symptoms she was treated 
with non-steroidal anti-inﬂ ammatory drugs and glucocor-
ticoids in varying doses, with no symptomatic relief. 
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 On physical examination, she had arthritis of both wrists 
and symmetrical polyarthralgia of multiple MCF joints. 
Remaining physical examination was unremarkable, with-
out any skin changes. 
 INVESTIGATIONS 
 Blood tests showed elevated inﬂ ammatory parameters (eryth-
rocyte sedimentation rate 67 mm/h and C reactive protein 2.1 
mg/dl), positive rheumatoid factor (RF) of 311 and a highly 
positive anticitrullinated protein antibody 251 U/ml. 
 Hands radiography revealed no erosive lesions, only 
juxta-articular osteopaenia ( ﬁ gure 1A,B ). 
 In this context, according to American College of 
Rheumatology/European League Against Rheumatism 
2010 criteria, the diagnosis of RA was admitted. 
 At this point, screening for Mycobacterial infection or 
latent disease was not performed. 
 TREATMENT 
 The patient was treated with disease-modifying antirheu-
matic drugs (DMARD), initially with methotrexate (MTX) 
and a low dose of prednisolone. The dose of MTX was 
increased progressively to 20 mg/week. Over 1 year, 
two more DMARDs were associated – sulfasalazine and 
hydroxychloroquine at maximum tolerable doses. There 
was no signiﬁ cant clinical improvement, maintaining pol-
yarthritis and polyarthralgia associated with marked limi-
tation of daily activities. 
 Before starting biological therapy with antitumour 
necrosis factor-α, a delayed hypersensitivity skin test reac-
tion using a puriﬁ ed protein derivative test was performed 
which proved to be highly positive (25 mm). A chest radi-
ography was normal ( ﬁ gure 2 ). 
 Considering that epidemiological information was irrel-
evant, interferon γ release assay for  M tuberculosis was con-
ducted and was negative. 
 Given the previous history of Hansen’s disease, the 
patient’s medical history was investigated and which sug-
gested that she had interrupted triple therapy for leprosy 
(served for 5 months only). The therapy was stopped on 
its own initiative following an episode of optic neuritis, 
probably resulting from dapsone. 
 At this time the diagnosis of RA was questioned. Was it 
RA or leprous arthritis? 
 OUTCOME AND FOLLOW-UP 
 Currently, the patient is treated with two DMARDs, MTX 
20 mg/week and sulfasalazine 2 g/day, keeping ﬂ are-ups 
of joint inﬂ ammation. These episodic ﬂ ares are control-
led with anti-inﬂ ammatory medication and alternate with 
periods of almost remission of articular symptoms. 
 DISCUSSION 
 Leprosy can present a great variety of signs and symptoms 
including arthralgia and arthritis similar to that seen in 
some rheumatic diseases. The articular involvement in lep-
rosy is considered to be the third most frequent manifesta-
tion, after dermatological and neurological involvement. 8 
 Leprosy typically affects the skin (macules, plaques, 
papules or nodules, which are hypopigmented and anaes-
thetic) and the peripheral nervous system (mononeuropa-
thy, mononeuritis multiplex or peripheral neuropathy). 5 
 Involvement of the musculoskeletal is a commonly 
known manifestation, however it’s often underdiagnosed. 
 To date, there has been no formal classiﬁ cation of arthri-
tis in leprosy. However, taking into account the existing 
bibliographic data, arthritis in leprosy can be divided into 
two main groups: 
 Acute arthritis of lepra reaction 1. 
 Chronic arthritis 2. 
 Acute arthritis in leprosy usually occurs as part of lepra 
reactions – typically, type I reactions, in patients with 
borderline or paucibacillary disease or type II reactions in 
patients with lepromatous leprosy. 9 Also a chronic, relaps-
ing, symmetrical, inﬂ ammatory, peripheral polyarthritis 
affecting primarily the wrists, metacarpal and proximal 
interphalangeal joints of the hands with a RA – like distri-
bution associated with leprosy has been described. 10  11 
 Because of similarities in the presentation of arthri-
tis and the joints involved, leprous arthritis frequently 
simulates RA. The absence of nodules or extra-articular 
Figure 1 Radiography of hands revealed no erosive lesions, only 
juxta-articular osteopaenia.
Figure 2 Normal thorax radiography.
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manifestations, males being more commonly affected than 
females and response to antileprosy treatment are consid-
ered some of the clinical distinguishing features between 
this two entities. 12 
 Radiological abnormalities in patients of arthritis due to 
leprosy can range from normal joints to joint subluxations 
and complete destruction. 5 
 In leprosy, the presence of autoantibodies associated 
with systemic manifestations similar to those found in 
rheumatic diseases can lead to misdiagnosis of these dis-
eases. Besides the large variability in prevalence of differ-
ent autoantibodies in patients with leprosy reported in the 
literature, there are few studies correlating the presence of 
autoantibodies to the articular manifestations in this dis-
ease. 13 RF is reported as positive in 70–80% of patients 
with RA; however, its speciﬁ city is limited since RF is also 
detected in sera from healthy older individuals and patients 
with various other autoimmune and infectious diseases, 
including leprosy. 8 Anti-CCP antibodies are considered to 
be highly speciﬁ c for the diagnosis of RA. 
 Makrygiannakis et al found that citrullinisation is a com-
mon process in inﬂ ammation, suggesting that this process 
is inﬂ ammation dependent rather than disease depend-
ent. In this study, biopsy specimens were obtained from 
patients with inﬂ ammatory conditions such as RA, poly-
myositis (PM), inﬂ ammatory bowel disease (IBD) and 
recurrent tonsillitis were studied. Citrullinated proteins 
were found in 100% of the cases of RA, PM and chronic 
tonsillitis and in 70% of the active IBD lesions. 14 
 Recent published studies searched anti-CCP antibodies 
by ELISA in infectious diseases, and the ﬁ nding of positiv-
ity, ranging from 0% to 37%, was higher in Mycobacterial 
pulmonary tuberculosis, putting in doubt the speciﬁ city of 
this test for the diagnosis of RA. Besides tuberculosis, anti-
CCP antibodies were found in a low percentage in numer-
ous infectious diseases (hepatitis C, hepatitis B, Hansen 
disease, untreated visceral leishmaniasis, Lyme disease, 
Chagas disease, HIV patients, HTLV-I positive patients, 
mononucleosis and Yersinia infection); however, there is a 
great variability in its frequency in different studies, prob-
ably due to methodological variations. 7 
 The symptoms the patient exhibits would allude to a 
diagnosis of either a leprous or a RA. 
 Some points favouring the diagnosis of RA are the 
fact that is a female patient, the presence of high levels 
of autoantibodies speciﬁ c for RA (anti-CCP and RF) and 
the absence of neuro-cutaneous manifestations suggesting 
leprosy. 
 Multiple studies have been suggested an association 
between smoking and RA. Hutchinson  et al propose the 
hypothesis that prolonged heavy cigarette smoking, but not 
smoking itself, results in increased RF production, explain-
ing in part the relation of increasing pack years smoked 
and the association with RA. 15 Lundstrom  et al described 
a positive association between smoking and the develop-
ment of anti-CCP positive RA. 16 The described patient was 
a heavy smoker of about 45 pack years. This is a positive 
fact favouring the diagnosis of a seropositive RA. 
 However, after 10 years of evolution of the arthritis it 
remains non-erosive and there was no improvement with 
the introduction of targeted therapy for RA, with multiple 
DMARDs and corticosteroids. 
 The fact that the onset of joint complaints coincide 
with the appearance of skin lesions and the diagnosis of 
Hansen’s disease, favours the eventual diagnosis of leprous 
arthritis. 
 A positive response causing reaction to tuberculin test 
has been occasionally described in patients with lepro-
matous leprosy. Although the mechanism is not clearly 
understood, it is suggested that a coincidence of delayed 
hypersensitivity to tuberculin and a less delayed phenom-
enon of excessive local edema to systemic features may be 
responsible for exaggerated changes. 17 
 The role of Mycobacteria as a trigger factor in the patho-
genesis of RA has been suggested. Holoshitz  et al described 
that peripheral blood and synovial ﬂ uid T-Iymphocytes 
from patients with RA showed increased reactivity to a 
mycobacterial fraction that cross-reacted with articular 
cartilage constituents, especially in patients with 1–10 
years of disease duration. The response was considered 
speciﬁ c since there was no reactivity to other mitogens 
or streptococcal antigens, suggesting a direct relationship 
between the Mycobacterial antigens and the pathogenesis 
of RA. 18 
 Regardless of whether the diagnosis is RA, leprous 
arthritis or an overlap of these two entities, the therapeu-
tic approach is necessarily more complicated, taking into 
account the adverse effects associated with both speciﬁ c 
therapy. 
 Recently, some cases of leprosy have been reported 
among patients born and resident in countries without lep-
rosy, after treatment with anti-TNF α agents – inﬂ iximab 
and adalimumab. 9  19 
 In conclusion, in order to avoid devastating conse-
quences associated with therapeutic interventions, this 
case highlights the importance of awareness of leprosy and 
its various presentations even in the geographical regions 
where this disease is not endemic. 
 Learning points 
 ▶  Arthritis in leprosy is common but usually under-
recognised, being the third most common symptom. 
 Arthritis can be present in all types of Hansen’s  ▶
disease and in patients without reactions. 
  ▶ M leprae may trigger chronic immunological responses 
in genetically predisposed individuaIs, conditioning a 
chronic, perpetuated arthritis. 
 Articular manifestations of leprosy can mimic RA and  ▶
other autoimmune diseases. 
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